It shares homology with the epidermal growth factor receptor and intrinsic tyrosine kinase activity HER-2/neu gene is amplified and overexpressed in 25-30% of human breast and ovarian cancers. Overexpression of the protein as determined by immunohistochemistry
is associated with poor prognosis (12).
One of the most important mammalian cell cycle checkpoint proteins is the tumor suppressor protein p53. In normal undamaged cells p53 is rapidly degraded. However when cells are treated with DNA damage-inducing
agents there is a transient accumulation of p53 protein and it is activated as a transcription factor. In several types of human cancers p53 is mutated34. Human p53 protein has been shown to be phosphorylated at several N-terminal and C-terminal sites that affect site-specific DNA binding and interaction with other cellular and viral proteins in vitro (5-10). Phosphorylation at serines 6 9 15 20 33 37 occur after cells are exposed either to ionizing radiation or to UV light (1112). Serines 6 and 15 were demonstrated to be one of the strongest and earliest phosphorylated sites in response to DNA damage-induced posttranslational modifications (13 14).
With a focus on providing targeted solutions for cancer research AnaSpec a leading provider of integrated proteomics solutions offers a highly specific selection of c-erbB-2 (HER-2/ neu) and p53 polyclonal antibodies. AnaSpecs collection of p53 antibody products includes both phosphospecific and non-phosphospecific solutions.
Anti-P53 (pSer6) phospho-specific
Anti-P53 (Paired6) non-phospho-specific
Anti-P53 (pSer9) phospho-specific
Anti-P53 (Paired9) non-phospho-specific
Anti-P53 (pSer15) phospho-specific
Anti-P53 (Paired15) non-phospho-specific
For more information on AnaSpecs cancer research antibodies visit www.anaspec.com
1. Hudson LG. et al. J. Biol. Chem. 265 2389 (1990).
2. Reese DM and DJ. Slamon. Stem Cells 15 1 (1997).
3. Brown JM et al (1999) Cancer Res. 59:1391-1399
4. Albrechtsen N et al (1999) Oncogene 18:7706-7717
5. Wang L. et al (2001) J. Biol Chem. 276 43604 (2001).
6. Xirodimas D et al (2001) Oncogene 20 (36):4972-83
7. Backlund MG et al (2001) Cancer Res. 61(17): 6577-82
8. Sakaguchi K et al (2000) J. Biol. Chem. 275:9278-83
9. Banin S et al (1998) Science 281: 1674-1677
10. Canman CE et al (1998) Science 281: 1677-1679
11. Burns TF et al J. cell Physiol. 181: 231-239
12. Oren M et al (1999) J. Biol. Chem 274:36031-36034
13. Lakin ND et al (1999) Oncogene 18: 7644-7655
14. Higashimoto Y et al (2000) J Biol Chem. 275:23199-23203